$311 Million is the total value of Samsara BioCapital, LLC's 32 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 42.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FMTX | New | Forma Therapeutics Holdings, Inc. | $73,379,000 | – | 1,578,388 | +100.0% | 23.60% | – |
| SWTX | Sell | Springworks Therapeutics Inc | $23,409,000 | +38.7% | 557,356 | -10.9% | 7.53% | -22.5% |
| ODT | Sell | Odonate Therapeutics Inc | $21,022,000 | +45.7% | 496,505 | -5.0% | 6.76% | -18.6% |
| PRNB | Sell | Principia Biopharma Inc | $20,505,000 | -13.9% | 342,946 | -14.5% | 6.60% | -51.9% |
| ICPT | Intercept Pharmaceuticals Inc | $19,341,000 | -23.9% | 403,688 | 0.0% | 6.22% | -57.5% | |
| ALLK | Sell | Allakos Inc | $17,524,000 | +45.4% | 243,868 | -10.0% | 5.64% | -18.8% |
| ISEE | Buy | Iveric Bio, Inc. | $17,189,000 | +479.3% | 3,370,478 | +290.8% | 5.53% | +223.8% |
| SYRS | Sell | Syros Pharmaceuticals Inc | $15,866,000 | +65.3% | 1,571,903 | -9.0% | 5.10% | -7.6% |
| STRO | Buy | Sutro BioPharma Inc | $13,002,000 | +13.2% | 1,675,579 | +48.9% | 4.18% | -36.7% |
| BCEL | Sell | Atreca Inc | $10,859,000 | +9.9% | 510,296 | -14.5% | 3.49% | -38.6% |
| AGLE | New | Aeglea BioTherapeutics, Inc. | $8,949,000 | – | 967,500 | +100.0% | 2.88% | – |
| GERN | New | Genron Corporation | $8,481,000 | – | 3,890,220 | +100.0% | 2.73% | – |
| ARAV | Aravive Inc | $6,705,000 | +102.1% | 576,066 | 0.0% | 2.16% | +12.9% | |
| RYTM | Rhythm Pharmaceuticals Inc | $6,161,000 | +46.5% | 276,289 | 0.0% | 1.98% | -18.1% | |
| FULC | New | Fulcrum Therapeutics, Inc. | $5,379,000 | – | 294,118 | +100.0% | 1.73% | – |
| PTLA | Buy | Portola Pharmaceuticals Inc | $5,279,000 | +363.5% | 318,429 | +99.3% | 1.70% | +158.8% |
| PIRS | Pieris Pharmaceuticals Inc | $5,203,000 | +40.9% | 1,620,249 | 0.0% | 1.67% | -21.3% | |
| HOOK | Sell | Hookipa Pharma Inc | $4,651,000 | +6.3% | 400,245 | -24.5% | 1.50% | -40.6% |
| ACRS | Aclaris Therapeutics, Inc. | $4,225,000 | +55.8% | 2,608,117 | 0.0% | 1.36% | -12.9% | |
| AIMT | Aimmune Therapeutics, Inc. | $3,886,000 | +15.9% | 232,571 | 0.0% | 1.25% | -35.2% | |
| KALA | Buy | Kala Pharmaceuticals Inc | $3,564,000 | +533.0% | 339,102 | +429.0% | 1.15% | +254.0% |
| BLU | Sell | Bellus Health Inc | $3,450,000 | -11.9% | 333,631 | -15.4% | 1.11% | -50.8% |
| RCKT | Buy | Rocket Pharmaceuticals Inc | $2,892,000 | +61.7% | 138,197 | +7.8% | 0.93% | -9.6% |
| KALV | KalVista Pharmaceuticals Inc | $2,035,000 | +58.1% | 168,174 | 0.0% | 0.66% | -11.6% | |
| Catabasis Pharmaceuticals Inc | $1,929,000 | +54.9% | 300,000 | 0.0% | 0.62% | -13.4% | ||
| SLNO | New | Soleno Therapeutics, Inc. | $1,665,000 | – | 750,000 | +100.0% | 0.54% | – |
| UROV | Urovant Sciences Ltd | $1,550,000 | +6.7% | 157,480 | 0.0% | 0.50% | -40.3% | |
| NGM | New | NGM Biopharmaceuticals, Inc. | $959,000 | – | 48,602 | +100.0% | 0.31% | – |
| ASMB | New | Assembly Biosciences Inc. | $694,000 | – | 29,740 | +100.0% | 0.22% | – |
| AKRO | Sell | Akero Therapeutics, Inc. | $554,000 | -47.7% | 22,234 | -55.5% | 0.18% | -70.8% |
| AMRN | Sell | Amarin Corp PLCspons adr new | $346,000 | -55.7% | 50,000 | -74.4% | 0.11% | -75.3% |
| VRNA | New | Verona Pharma PLC.sponsored ads | $203,000 | – | 43,456 | +100.0% | 0.06% | – |
| BLUE | Exit | Bluebird Bio Inc | $0 | – | -24,790 | -100.0% | -0.66% | – |
| SNSS | Exit | Sunesis Pharmaceuticals Inc | $0 | – | -5,938,215 | -100.0% | -1.42% | – |
| MLND | Exit | Millendo Therapeutics Inc | $0 | – | -751,301 | -100.0% | -2.28% | – |
| LQDA | Exit | Liquidia Technologies Inc | $0 | – | -1,013,773 | -100.0% | -2.75% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Intercept Pharmaceuticals Inc | 20 | Q3 2023 | 24.0% |
| ALLAKOS INC | 20 | Q3 2023 | 23.0% |
| SUTRO BIOPHARMA INC | 20 | Q3 2023 | 10.1% |
| SYROS PHARMACEUTICALS INC | 16 | Q3 2022 | 11.6% |
| ATRECA INC | 16 | Q1 2023 | 7.4% |
| IVERIC BIO INC | 15 | Q2 2023 | 5.5% |
| ACLARIS THERAPEUTICS INC | 15 | Q3 2023 | 4.8% |
| RHYTHM PHARMACEUTICALS INC | 15 | Q3 2023 | 2.4% |
| ODONATE THERAPEUTICS INC | 14 | Q1 2022 | 14.9% |
| SPRINGWORKS THERAPEUTICS INC | 14 | Q4 2022 | 12.1% |
View Samsara BioCapital, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR/A | 2023-08-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR/A | 2023-02-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
View Samsara BioCapital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.